US Patent Number
8957035
Publication Date
2-17-2015
Abstract
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.
Assignees
University of Kentucky Research Foundation, Lexington, KY (US)
Application Number
12/304,450
Primary Class
05/15/2007
Recommended Citation
Ambati, Jayakrishna, "Toll like Receptor (TLR) Stimulation for Ocular Angiogenesis and Macular Degeneration" (2015). Ophthalmology and Visual Science Faculty Patents. 10.
https://uknowledge.uky.edu/ophthalmology_patents/10
